Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer ...

Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib , its next-generation oral TYK2 inhibitor, in ...

Quantum computing is a promising field with massive long-term potential, but it is still in its early commercialization phase ...

According to TII’s technical report, the hybrid approach allows Falcon H1R 7B to maintain high throughput even as response ...

Shares of Cyclerion Therapeutics climbed after the company entered an agreement to integrate Medsteer's technology into its lead program in development for treatment-resistant depression. The stock ...

1. Sentiment Trackers: AI tracks price direction, momentum shifts, and volume flow to show whether a stock is gaining ...

Maj. Gen. McKenna offers exclusive insights into the growing threats to the Arctic from China and Russia, and what NORAD is ...

Enterprise AI adoption surged in 2025, but scaling still lags. Explore 7 key enterprise AI adoption trends shaping 2026.

New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development - POTOMAC, MARYLAND / ACCESS Newswire / January 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ...

Cyclerion Therapeutics entered an agreement to integrate Medsteer's technology into CYC-126, its lead program in development for treatment-resistant depression.

While many see AI adoption as a technology problem, healthcare reveals that AI systems can work as intended and still ignore ...

ANELLO has developed an inertial navigation system based on its SiPhOG technology for reliable navigation in GNSS-denied ...